AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vacha, G. M.
Right arrow Articles by Corsi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vacha, G. M.
Right arrow Articles by Corsi, M.
Agricola
Right arrow Articles by Vacha, G. M.
Right arrow Articles by Corsi, M.

American Journal of Clinical Nutrition, Vol 38, 532-540, Copyright © 1983 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol

GM Vacha, G Giorcelli, N Siliprandi and M Corsi

Twenty-nine hemodialyzed patients with hypertriglyceridemia were given L-carnitine (20 mg/kg iv at the end of each dialysis) for 120 days and then placebo for the same duration in order to evaluate the lipid- lowering effects of the metabolite. A dramatic reduction in triglyceride levels was observed only in the group of patients (n = 12) with high basal triglyceride values, low levels of high-density lipoprotein-cholesterol, and with apoprotein A at the lower limit of normal range. During L-carnitine treatment these patients exhibited significantly increased high-density lipoprotein-cholesterol and apoprotein A. No rebound effects were observed. L-Carnitine did not provoke changes in the lipid parameters in the group (n = 17) with high basal triglyceride values, and normal high-density lipoprotein- cholesterol and apoprotein A. Hematocrit values increased in all the 29 patients during L-carnitine treatment. At the end of the experimental protocol, L-carnitine dosage was increased to 60 mg/kg iv (at the end of each dialysis) in four patients of the group of nonresponders and prolonged for 60 days. This produced a considerable reduction in triglyceride levels. The above results suggest that L-carnitine can be effective in the management of hypertriglyceridemia in the hemodialyzed patient especially when low high-density lipoprotein-cholesterol levels are present.


This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
B. Schreiber
Levocarnitine and Dialysis: A Review
Nutr Clin Pract, April 1, 2005; 20(2): 218 - 243.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by The American Society for Nutrition